NKTR Nektar Therapeutics

24.31
+0.32  (1%)
Previous Close 23.99
Open 23.85
Price To book 1215.50
Market Cap 3800322254
Shares 156,327,530
Volume 961,243
Short Ratio 10.65
Av. Daily Volume 1,142,821

SEC filingsSee all SEC filings

  1. 8-K - Current report 171096129
  2. 8-K - Current report 171052430
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016260
  4. 8-K - Current report 171015443
  5. 8-K - Current report 17977544

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 commencement of dosing announced September 12, 2017.
NKTR-214 + TECENTRIQ + KEYTRUDA (PROPEL)
Solid tumors - cancer
Phase 3 second trial did not meet endpoint - April 5, 2017.
Cipro DPI
Bronchiectasis
Phase 3 data released March 20, 2017 - endpoints met.
NKTR-181
Lower back pain
Phase 1/2 initial data released at ASCO June 5, 2017. Poster at ESMO September 9, 2017.
NKTR-214
Solid tumors - cancer
Phase 3 data due 4Q 2017.
Inhaled Amikacin Solution (BAY41-6551T)
Gram-Negative Pneumonia (INHALE 1)
Phase 3 topline data mid March 2015 did not reach primary endpoint.
Etirinotecan pegol NKTR-102 (BEACON)
Cancer - Metastatic Breast Cancer
Approved November 16, 2015.
ADYNOVATE
Hemophilia A
Approved September 16, 2014.
MOVANTIK (Naloxegol)
Opioid-induced constipation (OIC)

Latest News

  1. ETFs with exposure to Nektar Therapeutics : September 28, 2017
  2. Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe
  3. See what the IHS Markit Score report has to say about Nektar Therapeutics.
  4. Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member
  5. Should You Buy Nektar Therapeutics (NKTR) Now?
  6. Nektar Therapeutics Announces Seven Abstracts Accepted for Presentation at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
  7. Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate
  8. Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab)
  9. Nektar Therapeutics :NKTR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
  10. Surging Earnings Estimates Signal Good News for Nektar (NKTR)
  11. Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek®
  12. Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City
  13. Nektar Therapeutics breached its 50 day moving average in a Bullish Manner : NKTR-US : September 1, 2017
  14. Today's Research Reports on Trending Tickers: Nektar Therapeutics and Ionis Pharmaceuticals Inc.
  15. Nektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek®
  16. Nektar Therapeutics Earns Relative Strength Rating Upgrade; Hits Key Benchmark

SEC Filings

  1. 8-K - Current report 171096129
  2. 8-K - Current report 171052430
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 171016260
  4. 8-K - Current report 171015443
  5. 8-K - Current report 17977544
  6. 8-K - Current report 17975573
  7. 8-K - Current report 17968533
  8. S-8 - Securities to be offered to employees in employee benefit plans 17914273
  9. 8-K - Current report 17914059
  10. 8-K - Current report 17858269